Before the Open (Mar 6)

Good morning. Happy Tuesday.
The Asian/Pacific markets closed mostly up. Japan, China, Hong Kong, South Korea, Taiwan, Austria and Singapore all did very well; India and Indonesia were weak. Europe, Africa and the Middle East are currently mostly up. Germany, Greece, South Africa, Norway, Hungary, Sweden, Austria and the Czech Republic are up more than 1%. Futures in the States point towards a moderate gap up open for the cash market.
—————
VIDEO: Long Term Trades for the Market’s Net Leg Up
—————
The dollar is down. Bitcoin is down. Oil and copper are up. Gold and silver are up. Bonds are down.
Stock headlines from barchart.com…
Archer-Daniels-Midland (ADM +1.23%) was upgraded to ‘Buy’ from ‘Neutral’ at Citigroup with a price target of $49.
Bunge (BG +3.75%) was upgraded to ‘Buy’ from ‘Hold’ at Citigroup with a price target of $89.
Target (TGT -0.01%) fell over 1% in pre-market trading after it reported Q4 adjusted EPS of $1.37, below consensus of $1.38.
Domino’s Pizza (DPZ -1.56%) was rated new ‘Outperform’ at Baird with a price target of $260.
Analogic (ALOG -0.12%) rose nearly 6% in after-hours trading after it reported Q2 adjusted EPS of $1.27, well above consensus of 69 cents,
Nordstrom (JWN -2.15%) fell 2% in after-hour trading after its board rejected a $50 a share offer from the Nordstrom Family Group.
G1 Therapeutics (GTHX +4.98%) lost more than 1% in after-hours trading after it announced that it had commenced an underwritten public offering of 3.0 million shares of its common stock.
Quidel (QDEL -1.26%) gained 5% in after-hours trading after it received FDA clearance to market its Sofia Lyme FIA to be used with the Sofia 2 Fluorescent Immunoassay to aid in the diagnosis of Lyme disease.
Glycomimentrics (GLYC -5.90%) plunged 18% in after-hours trading when it announced it will launch its Phase 3 clinical trial to evaluate its GMI-1271 in patients with relapsed or refractory acute myeloid leukemia.
Freshpet (FRPT +1.58%) dropped 12% in after-hours trading after it reported Q4 net sales of $40.7 million, weaker than consensus of $41.1 million, and said it sees 2018 adjusted Ebitda greater than $20 million, below consensus of $22.3 million.
Nautilus (NLS +0.40%) slid nearly 7% in after-hours trading after it reported Q4 revenue of $127.8 million, weaker than consensus of $128.6 million.
Syndax Pharmaceuticals (SNDX +0.71%) fell over 8% in after-hours trading after it reported a Q4 loss of -80 cents a share, wider than consensus of -77 cents.
Fate Therapeutics (FATE +3.77%) dropped 5% in after-hours trading after it reported a Q4 loss of -29 cents a share, wider than consensus of -25 cents.
Aduro Biotech (ADRO +4.65%) climbed nearly 6% in after-hours trading after it received a $3 million development milestone payment from Merck for initiating a Phase 1 clinical trial of it santi-CD27 antibody.
Tintri (TNTR +1.79%) jumped over 13% in after-hours trading after it reported Q4 revenue of $28.9 million, better than consensus of $26.3 million.
Today’s Economic Calendar
8:55 Redbook Chain Store Sales
10:00 Factory Orders
7:00 PM Fed’s Reserve Gov. Lael Brainard: Economic and Monetary Policy Outlook
8:30 PM Fed’s Kaplan speech
Other…
today’s upgrades/downgrades from briefing.com
this week’s Earnings from Morningstar
this week’s Economic Numbers/Reports powered by ECONODAY